Skip to content
TrialScanner

NCT05680922

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Phase 1Active, not recruitingLEGNLead

Registry record

Lead sponsor
Legend Biotech USA Inc
Conditions
Small Cell Lung Cancer Extensive Stage; Large Cell Neuroendocrine Carcinoma of the Lung
Primary completion
Dec 2027Sponsor estimate
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Sponsor estimate: the sponsor registered this date in advance and can move it. A primary completion date is when the last participant is measured, not when results are announced.

Open NCT05680922 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.